|
1
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Zhang H, Merkher Y, Chen L, Liu N,
Leonov S and Chen Y: Recent advances in therapeutic strategies for
triple-negative breast cancer. J Hematol Oncol. 15:1212022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sukumar J, Gast K, Quiroga D, Lustberg M
and Williams N: Triple-negative breast cancer: Promising prognostic
biomarkers currently in development. Expert Rev Anticancer Ther.
21:135–148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poggio F, Bruzzone M, Ceppi M, Pondé NF,
La Valle G, Del Mastro L, de Azambuja E and Lambertini M:
Platinum-based neoadjuvant chemotherapy in triple-negative breast
cancer: A systematic review and meta-analysis. Ann Oncol.
29:1497–1508. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmid P, Salgado R, Park YH,
Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent
R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment
of high-risk, early-stage triple-negative breast cancer: Results
from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann
Oncol. 31:569–581. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gianni L, Huang CS, Egle D, Bermejo B,
Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, et
al: Pathologic complete response (pCR) to neoadjuvant treatment
with or without atezolizumab in triple-negative, early high-risk
and locally advanced breast cancer: NeoTRIP Michelangelo randomized
study. Ann Oncol. 33:534–543. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Song M, Yang Z, Huang X, Lin Y
and Yang H: Healthy lifestyles, systemic inflammation and breast
cancer risk: A mediation analysis. BMC Cancer. 24:2082024.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grassadonia A, Graziano V, Iezzi L, Vici
P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli
D, et al: Prognostic relevance of neutrophil to lymphocyte ratio
(NLR) in luminal breast cancer: A retrospective analysis in the
neoadjuvant setting. Cells. 10:16852021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cupp MA, Cariolou M, Tzoulaki I, Aune D,
Evangelou E and Berlanga-Taylor AJ: Neutrophil to lymphocyte ratio
and cancer prognosis: An umbrella review of systematic reviews and
meta-analyses of observational studies. BMC Med. 18:3602020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yildirim S, Dogan A, Akdag G, Yüksel Yasar
Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS,
et al: The role of laboratory indices on treatment response and
survival in breast cancer receiving neoadjuvant chemotherapy. Sci
Rep. 14:121232024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hortobagyi GN, Edge SB and Giuliano A: New
and important changes in the TNM staging system for breast cancer.
Am Soc Clin Oncol Educ Book. 38:457–467. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abusanad A: Utilizing peripheral blood
inflammatory biomarker (PBIB) to predict response to systemic
therapy in patients with breast cancer. J Family Med Prim Care.
12:3368–3373. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nambo-Venegas R, Enríquez-Cárcamo VI,
Vela-Amieva M, Ibarra-González I, Lopez-Castro L, Cabrera-Nieto SA,
Bargalló-Rocha JE, Villarreal-Garza CM, Mohar A, Palacios-González
B, et al: A predictive model for neoadjuvant therapy response in
breast cancer. Metabolomics. 21:282025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kusama H, Kittaka N, Soma A, Taniguchi A,
Kanaoka H, Nakajima S, Oyama Y, Seto Y, Okuno J, Watanabe N, et al:
Predictive factors for response to neoadjuvant chemotherapy:
Inflammatory and immune markers in triple-negative breast cancer.
Breast Cancer. 30:1085–1093. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun H, Liang J, Xue S, Zhang X, Ding M,
Zhu J, Nanding A, Liu T, Lou G, Gao Y, et al: Establishment and
clinical application of a prognostic index for inflammatory status
in triple-negative breast cancer patients undergoing neoadjuvant
therapy using machine learning. BMC Cancer. 24:15592024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamanouchi K and Maeda S: The efficacy of
inflammatory and immune markers for predicting the prognosis of
patients with stage IV breast cancer. Acta Med Okayama. 77:37–43.
2023.PubMed/NCBI
|
|
18
|
Hua X, Long ZQ, Huang X, Deng JP, Wen W,
He ZY, Guo L, Zhang WW and Lin HX: The preoperative systemic
inflammation response index (SIRI) independently predicts survival
in postmenopausal women with breast cancer. Curr Probl Cancer.
44:1005602020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Sun Y and Zhang Q: Prognostic
value of the systemic immune-inflammation index in patients with
breast cancer: A meta-analysis. Cancer Cell Int. 20:2242020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W, Ma G, Deng Y, Chen W, Liu Z, Chen F
and Wu Q: Systemic immune-inflammation index is a prognostic factor
for breast cancer patients after curative resection. Front Oncol.
11:5702082021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji Y and Wang H: Prognostic prediction of
systemic immune-inflammation index for patients with gynecological
and breast cancers: A meta-analysis. World J Surg Oncol.
18:1972020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polley MC, Leon-Ferre RA, Leung S, Cheng
A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA,
et al: A clinical calculator to predict disease outcomes in women
with triple-negative breast cancer. Breast Cancer Res Treat.
185:557–566. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Shi Z, Bai Y, Liu L and Cheng K:
Prognostic significance of systemic immune-inflammation index in
triple-negative breast cancer. Cancer Manag Res. 11:4471–4480.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang P, Yue W, Li W, Luo Y, Li Z, Shao Y
and He Z: Systemic immune-inflammation index and ultrasonographic
classification of breast imaging-reporting and data system predict
outcomes of triple-negative breast cancer. Cancer Manag Res.
11:813–819. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Kong X, Wang Z, Wang X, Fang Y and
Wang J: Pretreatment systemic inflammation response index in
patients with breast cancer treated with neoadjuvant chemotherapy
as a useful prognostic indicator. Cancer Manag Res. 12:1543–1567.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang C, Zhang S, Qiao K, Xiu Y, Yu X and
Huang Y: The pretreatment systemic inflammation response index as a
useful prognostic factor is better than lymphocyte to monocyte
ratio in breast cancer patients receiving neoadjuvant chemotherapy.
Clin Breast Cancer. 22:424–438. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong J, Sun Q, Pan Y, Lu N, Han X and Zhou
Q: Pretreatment systemic inflammation response index is predictive
of pathological complete response in patients with breast cancer
receiving neoadjuvant chemotherapy. BMC Cancer. 21:7002021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen M, Linstra R and van Vugt MATM:
Genomic instability, inflammatory signaling and response to cancer
immunotherapy. Biochim Biophys Acta Rev Cancer. 1877:1886612022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dikiy S and Rudensky AY: Principles of
regulatory T cell function. Immunity. 56:240–255. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Propper DJ and Balkwill FR: Harnessing
cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol.
19:237–253. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu C, Chu D, Kalantar-Zadeh K, George J,
Young HA and Liu G: Cytokines: From clinical significance to
quantification. Adv Sci (Weinh). 8:20044332021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qiu Y, Su M, Liu L, Tang Y, Pan Y and Sun
J: Clinical application of cytokines in cancer immunotherapy. Drug
Des Devel Ther. 15:2269–2287. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nicolas AM, Pesic M, Engel E, Ziegler PK,
Diefenhardt M, Kennel KB, Buettner F, Conche C, Petrocelli V,
Elwakeel E, et al: Inflammatory fibroblasts mediate resistance to
neoadjuvant therapy in rectal cancer. Cancer Cell. 40:168–184.
e132022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng X, Zhang H, Hamad A, Huang H and
Tsung A: Surgery-mediated tumor-promoting effects on the immune
microenvironment. Semin Cancer Biol. 86((Pt 3)): 408–419. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Takada M and Toi M: Neoadjuvant treatment
for HER2-positive breast cancer. Chin Clin Oncol. 9:322020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cho U, Park HS, Im SY, Yoo CY, Jung JH,
Suh YJ and Choi HJ: Prognostic value of systemic inflammatory
markers and development of a nomogram in breast cancer. PLoS One.
13:e02009362018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou N, Liu L, Li D, Zeng Q and Song X:
VCS parameters of neutrophils, monocytes and lymphocytes may
indicate local bacterial infection in cancer patients who accepted
cytotoxic chemotherapeutics. Eur J Clin Microbiol Infect Dis.
35:41–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeong J, Suh Y and Jung K: Context drives
diversification of monocytes and neutrophils in orchestrating the
tumor microenvironment. Front Immunol. 10:18172019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun H, Wang H, Pan H, Zuo Y, Zhao R, Huang
R, Xue Y and Song H: CD19 (+) B cell combined with prognostic
nutritional index predicts the clinical outcomes of patients with
gastric cancer who underwent surgery. Cancers (Basel). 15:25312023.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tan S, Li D and Zhu X: Cancer
immunotherapy: Pros, cons and beyond. Biomed Pharmacother.
124:1098212020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xie T, Huang AL, Xiang LY, Xue HC, Chen
ZZ, Ma AL, Yan HL and Yuan JP: Value of the deep learning automated
quantification of tumor-stroma ratio in predicting efficacy and
prognosis of neoadjuvant therapy for breast cancer based on
residual cancer burden grading. Zhonghua Bing Li Xue Za Zhi.
54:59–65. 2025.(In Chinese). PubMed/NCBI
|
|
44
|
Yu Y, Wu S, Xing H, Han M, Li J and Liu Y:
Development and validation of a novel model for predicting
prognosis of Non-PCR patients after neoadjuvant therapy for breast
cancer. Front Oncol. 11:6755332021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gass P, Lux MP, Rauh C, Hein A, Bani MR,
Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, et al:
Prediction of pathological complete response and prognosis in
patients with neoadjuvant treatment for triple-negative breast
cancer. BMC Cancer. 18:10512018. View Article : Google Scholar : PubMed/NCBI
|
